SAN FRANCISCO–(BUSINESS WIRE)–Elixir Medical, a developer of novel cardiovascular technologies, today announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES). The study met its primary endpoint of target lesion failure (TLF) with no TLF events rep
Other News
Heartpoint Global Wins Top Honor in TCT 2023 Shark Tank Innovation Competition
Award Recognizes Breakthrough Innovation for INTELLISTENT®, Paving the Way for Citizens Worldwide to Receive Affordable, Cutting-Edge Cardiac Care NEW YORK , Oct. 25, 2023 /PRNewswire/ — HeartPoint Global is pleased to announce that INTELLISTENT® the company’s novel multi-lumen stent…
Ventric Health Receives FDA 510(k) Clearance for Vivio®
Non-invasive medical device developed to quickly deliver the cardiovascular insights value-based care organizations need to reduce costs and improve patient lives PASADENA, Calif., Oct. 25, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider…
Philippe Généreux, MD Presents Novel Research on Aortic Stenosis from egnite, Inc.’s Database at Transcatheter Cardiovascular Therapeutics Conference 2023
ALISO VIEJO, Calif.–(BUSINESS WIRE)– #digitalhealth–Key Findings: Patients With Aortic Stenosis (AS) Have Substantial Untreated Mortality Risk Across All Levels of AS, but AVR Remains Low
Late-Breaking Data Showcase the Benefits of Abbott’s Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S….
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ — Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics…
Massachusetts General Hospital Researchers and Prevencio Announce AI-driven HART® CVE Blood Test Accuracy for Patients with Coronary Chronic Total Occlusion
KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., the AI-Powered Cardiac Blood Test Company, today announces the presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART® CVE blood test is highly accurate for risk assessment in patients with total blockage of a heart artery, also known as coronary Chronic Total Occlusion (CTO). Researchers from Massachusetts General Hospital (MGH) tested 241 patients with chronic total occlusion of at least one coronary (hea
Medinol Receives FDA Approval for Next Generation EluNIR-PERL™ Drug-Eluting Coronary Stent System
CoSo Health to exclusively distribute Medinol’s most advanced coronary DES in the U.S. DENVER and TEL AVIV, Israel, Oct. 24, 2023 /PRNewswire/ — Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the…
New Study Published in Cardiovascular Digital Health Journal Shows Implicity’s Algorithm Significantly Reduces AF Alert Burden in Remote Cardiac Monitoring
Research affirms Implicity’s algorithm* is highly effective at identifying patterns and classifying AF episodes into medically relevant events that require clinical action CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ — Implicity, a leader in remote patient monitoring (RPM) and cardiac…
Endologix’s DETOUR™ System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA’s Best Medical Technology
IRVINE, Calif.–(BUSINESS WIRE)– #DETOURSystem–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, proudly announces recent awards and nominations for its groundbreaking DETOUR System. Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral artery, by using conduits routed th
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet